Human consumption of food usually is evenly distributed. Epidemiology

Size: px
Start display at page:

Download "Human consumption of food usually is evenly distributed. Epidemiology"

Transcription

1 Epidemiology Fasting and Nonfasting Lipid Levels Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction Anne Langsted, BMSc; Jacob J. Freiberg, MD; Børge G. Nordestgaard, MD, DMSc Background Lipid profiles are usually measured after fasting. We tested the hypotheses that these levels change only minimally in response to normal food intake and that nonfasting levels predict cardiovascular events. Methods and Results We cross-sectionally studied individuals 2 to 95 years of age from the Copenhagen General Population Study. We also studied 9319 individuals 2 to 93 years of age from the Copenhagen City Heart Study, 1166 of whom developed cardiovascular events during 14 years of follow-up. Compared with fasting levels, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, and albumin levels were reduced up to 3 to 5 hours after the last meal; triglycerides levels were increased up to 6 hours after the last meal; and non-hdl cholesterol level, apolipoprotein A1 level, apolipoprotein B level, ratio of total cholesterol to HDL cholesterol, and ratio of apolipoprotein B to apolipoprotein A1 did not change in response to normal food intake. The maximum changes after normal food and fluid intake from fasting levels were.2 mmol/l for total cholesterol,.2 mmol/l for low-density lipoprotein cholesterol,.1 mmol/l for HDL cholesterol, and.3 mmol/l for triglycerides. Highest versus lowest tertile of nonfasting total cholesterol, non-hdl cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, ratio of total cholesterol to HDL cholesterol, and ratio of apolipoprotein B/apolipoprotein A1 and lowest versus highest tertile of nonfasting HDL cholesterol and apolipoprotein A1 predicted 1.7- to 2.4-fold increased risk of cardiovascular events. Conclusions Lipid profiles at most change minimally in response to normal food intake in individuals in the general population. Furthermore, nonfasting lipid profiles predicted increased risk of cardiovascular events. (Circulation. 28; 118: ) Key Words: apolipoproteins cardiovascular diseases lipids lipoproteins Human consumption of food usually is evenly distributed throughout the day (ie, in the form of 3 meals and snacks in between). The fasting state occurs, by definition, after an 8-hour fast 1 ; thus, most humans find themselves in the nonfasting state for the majority of a 24-hour period, perhaps with the exception of the early morning hours. Clinical Perspective p 256 Despite this fact, plasma lipids, lipoproteins, and apolipoproteins for cardiovascular risk prediction are usually measured in the fasting state. 1 3 A main reason is the increase in triglyceride levels seen during a fat tolerance test, in which patients typically consume 1 g fat per 1 kg body weight. 4,5 However, levels of nonfasting triglycerides are better at predicting future cardiovascular events than levels of fasting triglycerides. 6,7 Furthermore, it is possible that nonfasting levels of lipids, lipoproteins, and apolipoproteins differ only minimally from levels in the fasting state simply because most people consume far less fat at ordinary meals than during a fat tolerance test. We tested the hypothesis that levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, non-hdl cholesterol, triglycerides, apolipoprotein B, and apolipoprotein A1 and the ratios of total cholesterol to HDL cholesterol and apolipoprotein B to apolipoprotein A1 change only minimally in response to normal food intake in individuals in the general population. For this purpose, we cross-sectionally examined individuals from the Copenhagen General Population Study. We also tested whether nonfasting levels of these lipids, lipoproteins, and apolipoproteins predict increased risk of cardiovascular events. To test these hypotheses, we used Received February 6, 28; accepted August 21, 28. From the Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev (A.L., J.J.F., B.G.N.), and Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen (B.G.N.), Denmark. The online-only Data Supplement can be found with this article at Correspondence to Børge G. Nordestgaard, Professor, Chief Physician, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-273 Herlev, Denmark. brno@heh.regionh.dk 28 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA

2 248 Circulation November 11, individuals from the Copenhagen City Heart Study whom we followed up for 14 years, during which time 1166 experienced cardiovascular events. Methods Participants Participants gave written informed consent. The studies were approved by the Herlev Hospital and by the Danish ethical committee for Copenhagen and Frederiksberg (No /91 and 1-144/ 1). The participants in the 2 studies filled out the same questionnaire and were examined similarly; however, information on time since the last meal was obtained only in the cross-sectional study and on different individuals, not on the same individuals several times. Cross-Sectional Study On the basis of the Danish Central Person Registration number, the Copenhagen General Population Study (23 to 26 examination) and Copenhagen City Heart Study (21 to 23 examination) 7 recruited participants randomly from the general population of Copenhagen, Denmark; because 81% of all participants were from the Copenhagen General Population study, we refer only to this study for the cross-sectional data. Importantly, lipid levels were measured in the same laboratory for both studies, and the collection of all other data was identical for the 2 studies. From 21 through 26, we examined men and women 2 to 95 years of age, 142 of whom were excluded as outliers (ie, participants with fasting or nonfasting levels of total cholesterol, LDL cholesterol, HDL cholesterol, non-hdl cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, or albumin outside 3 SD from the mean). We excluded outliers because chance clustering of outliers in 1 group versus another could bias the results. This left individuals for the present cross-sectional analyses. The examination included a self-administered questionnaire on detailed medical history and lifestyle, which was checked by an examiner on the day of attendance. In addition, a physical examination was performed, and blood samples were drawn for measurements of total cholesterol, LDL cholesterol, HDL cholesterol, non-hdl cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, and albumin. Before blood sampling, participants were asked when they had eaten their last meal ( to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, or 8 hours ago [fasting]); this information was obtained to test the hypothesis of the present study. The time of day for blood sampling also was registered (between 8 AM and 7 PM). Prospective Study The Copenhagen City Heart Study is a prospective cardiovascular study of the Danish general population. 7 At the third examination in 1991 through 1994, participated. In the present study, we included 9319 individuals from this examination who had nonfasting total cholesterol, LDL cholesterol, HDL cholesterol, non-hdl cholesterol, triglycerides, apolipoprotein B, and apolipoprotein A1 determined and who were free of ischemic cardiovascular disease at baseline. End points used in the study were fatal and nonfatal ischemic cardiovascular events, including myocardial infarction and ischemic stroke. 7,8 Participants were followed up through the use of their unique Central Person Registration number from baseline, defined as the date of participation in the 1991 through 1994 examination, and until the occurrence of an ischemic cardiovascular event, death, or July 27, whichever came first. Follow-up was 1% complete. Information on diagnosis of ischemic cardiovascular events was collected by reviewing all hospital admissions and diagnoses entered in the Danish National Hospital Discharge Register and all causes of death entered in the Danish National Register of Causes of Death and was verified by medical records from hospitals and general practitioners. 7,8 Table 1. Characteristics of Individuals From the General Population Characteristics Cross-Sectional Study, CGPS Prospective Study, CCHS N Women, % Age, y 6 (5 69) 59 (46 7) Total cholesterol, mmol/l 5.6 ( ) 6. ( ) Non-HDL 4. ( ) 4.4 ( ) cholesterol, mmol/l LDL cholesterol, mmol/l 3.2 ( ) 3.7 ( ) HDL cholesterol, mmol/l 1.6 (1.3 2.) ( ) Triglycerides, mmol/l 1.4 (1. 2.1) ( ) Apolipoprotein A1, mg/dl 154 ( ) 139 (122 16) Apolipoprotein B, mg/dl 19 (9 131) 84 (7 1) Total cholesterol/hdl ( ) 3.9 ( ) cholesterol Apolipoprotein.7 (.6.9).6 (.5.8) B/apolipoprotein A1 Albumin, mol/l 615 ( ) Body mass index, kg/m 2 26 (23 28) 25 (22 28) Alcohol intake, g/d 14 (5 26) 1 (3 2) Hypertension, % Physical inactivity, % 8 12 Smokers, % Diabetes mellitus, % 5 4 Lipid-lowering therapy, % 8.5 Postmenopausal, women only, % Postmenopausal with HRT, women only, % CGPS indicates Copenhagen General Population Study; CCHS, Copenhagen City Heart Study, 1991 to 1994 examination; and HRT, hormone replacement therapy. Continuous variables are shown as median (interquartile range). Risk Factors Men consuming 36 g of alcohol per day ( 21 U/wk) and women consuming 24 g/d ( 14 U/wk) were defined as heavy alcohol drinkers. Hypertension was defined as systolic blood pressure 14 mm Hg, diastolic blood pressure 9 mm Hg, or use of antihypertensive medication. Smokers were active smokers. Physical inactivity was leisure-time activity of 4 h/wk and predominantly sedentary work. Diabetes mellitus was self-reported disease, use of insulin or oral hypoglycemic pills, or a nonfasting plasma glucose 11 mmol/l. Participants reported lipid-lowering therapy, and women reported menopausal status and use of hormone replacement therapy. Analysis Fresh blood samples were analyzed with standard hospital assays to measure plasma levels of total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, apolipoprotein A1, apolipoprotein B, and albumin (Konelab, Helsinki, Finland or Boehringer Mannheim, Mannheim, Germany) (Table I of the online-only Data Supplement); coefficients of variations varied from 2% to 4%, and drift over time from year to year varied from 1% to 4%. Assays were followed up daily for precision and 4 to 12 times yearly for accuracy with a Scandinavian quality control program. LDL cholesterol was calculated from the Friedewald equation if triglycerides were 4 mmol/l 1

3 Langsted et al Normal Food Intake, Lipid Profiles, and CVD Cholesterol (mmol/l) *** ** * *** *** *** Total cholesterol Non-HDL cholesterol ** LDL cholesterol ** *** *** ** * HDL cholesterol Fasting Time since last meal (hours) N= and measured directly at higher triglyceride levels. Non-HDL cholesterol was total cholesterol minus HDL cholesterol. Statistical Analysis We used Stata 9.2 (Stata Corp, College Station, Tex). Plasma triglycerides and HDL cholesterol were skewed and hence were transformed logarithmically to approach normal distributions. In the cross-sectional study, because age, sex, and other covariates differed as a function of time since the last meal (online-only Data Supplement Table II) and because age, sex, and other covariates influence lipid levels, general linear models were used to adjust for age and sex; for age, sex, and albumin; or for all covariates listed in online-only Data Supplement Table II. For the adjusted analyses, men and women were stratified into 5-year age groups from 2 to 8 years of age, and albumin values were stratified according to time since the last meal (or time of sampling). Differences in levels of lipids, lipoproteins, apolipoproteins, and albumin as a function of time since the last meal ( to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6to7,7to8,or 8 hours) were tested with the Student t test between fasting levels ( 8 hours) and the 8 other time points. Differences in these levels also were tested according to time of day of blood sampling, with levels sampled between 8 and 9 AM as reference. All tests were corrected for multiple comparisons with the Bonferroni method (P values were multiplied by the number of parallel tests). 9 In the prospective study, Cox proportional-hazards regression models with age, blood pressure, smoking status, use of lipidlowering drugs, and use of hormone therapy as covariates or with age, blood pressure, smoking status, use of lipid-lowering drugs, use of hormone therapy, body mass index, diabetes mellitus, and high-sensitivity C-reactive protein levels as covariates were used to estimate hazard ratios for ischemic cardiovascular events by tertiles of total cholesterol, non-hdl cholesterol, LDL cholesterol, HDL Apolipoprotein (mg/dl) Albumin (micromol/l) *** *** *** *** *** *** *** *** Apolipoprotein A1 Apolipoprotein B *** *** Triglycerides Albumin Total cholesterol/hdl cholesterol Apolipoprotein B/Apolipoprotein A Fasting Time since last meal (hours) Figure 1. Levels of lipids, lipoproteins, apolipoproteins, and albumin as a function of time since the last meal. Values are means with SE adjusted for sex and age. With adjusted values, Bonferroni-corrected P values on unpaired Student t test vs fasting levels ( 8 hours since the last meal) are as follows: *P.5, **P.1, and ***P.1. cholesterol, apolipoprotein A1, apolipoprotein B, triglycerides, ratio of apolipoprotein B to apolipoprotein A1, and ratio of total cholesterol to HDL cholesterol. Hazard ratios were corrected for regression dilution bias with a nonparametric method. 7,1 We used the nonparametric method because it does not rely on assumptions of constant variances. For this correction, we used nonfasting values from 4441 individuals not on lipid-lowering therapy who attended both the baseline 1991 to 1994 examination and the 21 to 23 examination; however, the main analyses were conducted on 9319 individuals. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. Results Characteristics of individuals from the Danish general population, the Copenhagen General Population Study and the Copenhagen City Heart Study, are shown in Table 1; 1% and 99% of the participants were white and of Danish descent in the 2 studies, respectively. Five percent were on lipidlowering therapy in the cross-sectional study; when these 5% were excluded from the analyses, the results were similar to those presented below. Time Since the Last Meal After adjustment for age and sex and compared with fasting levels, total cholesterol, LDL cholesterol, HDL cholesterol, and albumin were reduced for up to 3 to 5 hours after the last meal, whereas triglycerides increased for up to 6 hours after the last meal (Figure 1). Levels of non-hdl cholesterol, Triglycerides (mmol/l) Ratio

4 25 Circulation November 11, 28 Cholesterol (mmol/l) N= * Total cholesterol Non-HDL cholesterol * * LDL cholesterol HDL cholesterol Fasting Time since last meal (hours) apolipoprotein A1, and apolipoprotein B and ratios of total to HDL cholesterol and apolipoprotein B to A1 did not change in response to normal food intake. After further adjustment for all covariates shown in online-only Data Supplement Table II, the results were similar to those shown in Figure 1. In addition, if we based the analyses in Figure 1 on all individuals without excluding outliers, the results were similar (online-only Data Supplement Figure I). Reduced levels of albumin after normal food intake are likely caused by hemodilution resulting from fluid intake; therefore, we also corrected all values in Figure 1 for mean changes in albumin levels as a function of time since the last meal (Figure 2). After this adjustment, total cholesterol, LDL cholesterol, and albumin levels no longer differed as a function of time since the last meal. However, plasma triglycerides and apolipoprotein B were increased and HDL cholesterol was decreased for up 4 to 6 hours after normal food intake even after this adjustment. Time of Day for Blood Sampling In individuals in the general population with normal food intake, levels of total cholesterol, LDL cholesterol, HDL cholesterol, non-hdl cholesterol, apolipoprotein A1, and apolipoprotein B did not differ substantially, depending on what time of day blood was drawn (Figure 3). However, triglyceride levels were higher between noon and 5 PM compared with earlier or later in the day. Albumin levels were higher later in the day compared with between 8 and 9 AM, Apolipoprotein (mg/dl) Albumin (micromol/l) ** ** ** Apolipoprotein A1 Apolipoprotein B *** *** *** *** *** Triglycerides Albumin Fasting Time since last meal (hours) *** Total cholesterol/hdl cholesterol Apolipoprotein B/Apolipoprotein A1 Figure 2. Levels of lipids, lipoproteins, apolipoproteins, and albumin as a function of time since the last meal. Values are means with SE adjusted for sex, age, and albumin levels. With adjusted values, Bonferroni-corrected P values on unpaired Student t test vs fasting levels ( 8 hours since the last meal) are as follows: *P.5, **P.1, and ***P.1. possibly because of hemoconcentration. The rise in triglyceride levels from noon through 5 PM did not disappear after adjustment for albumin levels (data not shown). The results shown in Figure 3 were adjusted for age and sex; however, even after further adjustment for all covariates shown in Table II of the online-only Data Supplement, results were similar. Time Since the Last Meal Stratified for Time of Day Levels of total cholesterol and LDL cholesterol did not change in response to normal food intake when blood samples were drawn in the morning or afternoon, whereas these 2 variables decreased for up to 5 hours after normal food intake compared with fasting levels when blood samples were drawn in the evening (data not shown). Plasma triglycerides increased in response to normal food intake regardless of whether blood was drawn in the morning, afternoon, or evening (data not shown). Maximum Change in Lipids, Lipoproteins, and Apolipoproteins After normal food intake, individuals in the general population had a maximum mean change from fasting levels of.2 mmol/l for total cholesterol at to 2 hours after the last meal,.2 mmol/l for LDL cholesterol at to 2 hours,.1 mmol/l for HDL cholesterol at to 5 hours, and.3 mmol/l for triglycerides at 1 to 4 hours after the last meal Ratio Triglycerides (mmol/l)

5 Langsted et al Normal Food Intake, Lipid Profiles, and CVD Cholesterol (mmol/l) am 9-1 am 1-11 am am 12-1 pm Total cholesterol Non-HDL cholesterol LDL cholesterol * HDL cholesterol 1-2 pm 2-3 pm 3-4 pm 4-5 pm 5-6 pm 6-7 pm Time of day for blood sampling N= (Table 2 and Figure 1). These results were adjusted for age and sex; however, even after further adjustment for all covariates shown in online-only Data Supplement Table II, results were similar. Risk of Cardiovascular Events In the Copenhagen City Heart Study, we observed 1166 cardiovascular events (627 myocardial infarction events and 539 ischemic stroke events) during 14 years of follow-up. Highest versus lowest tertile of nonfasting total cholesterol, non-hdl cholesterol, LDL cholesterol, apolipoprotein B, triglycerides, ratio of total to HDL cholesterol, and ratio of apolipoprotein B to A1 and lowest versus highest tertile of nonfasting HDL cholesterol and apolipoprotein A1 predicted a 1.7- to 2.4-fold increase in risk of cardiovascular events (Table 3). Discussion We found that levels of lipids, lipoproteins, and apolipoproteins at most changed minimally in response to normal food intake in individuals in the general population. Furthermore, nonfasting levels of these lipids, lipoproteins, and apolipoproteins all predicted increased risk of cardiovascular events. To the best of our knowledge, no substantial evidence demonstrates that fasting lipid levels are superior to nonfasting levels for cardiovascular risk prediction. It is therefore reasonable to review the arguments often used in favor of fasting versus nonfasting lipid measurements, simply because Apolipoprotein (mg/dl) Albumin (micromol/l) am 9-1 am 1-11 am am 12-1 pm Apolipoprotein A1 Apolipoprotein B *** ** *** * * Triglycerides *** *** *** *** *** *** *** *** *** *** Albumin Total cholesterol/hdl cholesterol Apolipoprotein B/Apolipoprotein A1 1-2 pm 2-3 pm 3-4 pm 4-5 pm 5-6 pm 6-7 pm Time of day for blood sampling Figure 3. Levels of lipids, lipoproteins, apolipoproteins, and albumin as a function of time of day for blood sampling. Values are means with SE adjusted for sex and age. With adjusted values, Bonferroni-corrected P values on unpaired Student t test vs morning levels (at 8to9AM) are as follows: *P.5, **P.1, and ***P.1. * the fasting requirement possibly makes blood sampling unnecessarily difficult for millions of patients worldwide. One argument often presented in favor of measuring lipids, lipoproteins, and apolipoproteins in the fasting state is the increase in triglyceride levels seen during fat tolerance tests. 4,5,7 However, our findings show that levels of lipids, lipoproteins, and apolipoproteins after normal food intake differ only minimally from levels in the fasting state, probably because most people consume much less fat at ordinary meals than during a fat tolerance test. Another argument often presented is that calculating LDL cholesterol with the Friedewald equation requires fasting triglyceride measurement. 1 However, our data demonstrate that calculated LDL cholesterol changes only minimally in response to normal food intake and that increased nonfasting LDL cholesterol predicts increased risk of cardiovascular events. Therefore, it is tempting to speculate that the main reasons for measuring lipid levels in the fasting rather than the nonfasting state are simply that it has become the norm worldwide and that the fasting requirement has been applied in almost all randomized lipid-lowering trials. Total and LDL cholesterol levels were reduced for up to 3 to 4 hours after normal food intake; this reduction was paralleled by a similar fall in albumin levels. Therefore, and because total and LDL cholesterol levels did not change in response to normal food intake after adjustment for albumin levels, the explanation for the small reduction in total and Ratio Triglycerides (mmol/l)

6 252 Circulation November 11, 28 Table 2. Change in Lipids, Lipoproteins, and Apolipoproteins Compared With Fasting as a Function of Time Since the Last Meal in the General Population (Copenhagen General Population Study) Time Since Last Meal, h Characteristics n Total cholesterol, mmol/l.2 (.2.1).2 (.2.1).1 (.2.)*.1 (.1.) LDL cholesterol, mmol/l.2 (.3.1).2 (.2.1).1 (.2.1).1 (.2.) HDL cholesterol, mmol/l.1 (.1.).1 (.1.).1 (.1.).1 (.1.) Non-HDL cholesterol, mmol/l.1 (.2.).1 (.1.). (.1.). (.1.1) Triglycerides, mmol/l.2 (.2.3).3 (.2.3).3 (.2.3).3 (.2.4) Apolipoprotein A1, mg/dl 2.6 ( 4.7.5) 2.6 ( 4.7.6) 2. ( 4..1) 1. ( ) Apolipoprotein B, mg/dl.5 ( ).6 ( 2.8) 1.2 (.9 3.4) 2.6 (.4 4.8) Total cholesterol/hdl cholesterol. (.1.1).1 (..2).1 (..2).1 (..2) Apolipoprotein B/apolipoprotein A1. (.1.1). (.1.1). (.1.1). (.1.1) Albumin, mol/l 19 ( 23 15) 19 ( 23 15) 15 ( 19 11) 1 ( 14 6) (Continued) Values are mean change (95% confidence interval). Bonferroni corrected P values on Student t test (unpaired) vs fasting levels ( 8 hours since last meal): *P.5, P.1, and P.1. LDL cholesterol levels is most likely hemodilution resulting from fluid intake in relation to the meal. A similar fall in LDL cholesterol, but not in total cholesterol, from fasting levels was observed among 115 subjects 3 to 5 hours after a normal breakfast. 11 Interestingly, the National Cholesterol Education Program 2 advises that total cholesterol, but not LDL cholesterol, be used in the nonfasting state, whereas our data suggest that the change in the 2 after normal food intake is similar but minimal. Triglycerides increased and HDL cholesterol decreased in response to normal food intake even after the correction for albumin levels and thus correction for hemodilution due to fluid intake. Therefore, the changes in these levels are most likely due to food intake rather than fluid intake. Although the increases in triglycerides are likely attributable directly to fat intake, the parallel reduction in HDL cholesterol likely is due to bidirectional lipid exchange between triglyceride-rich lipoproteins and HDL particles: Lipid transfer proteins mediate transfer of triglycerides from triglyceride-rich lipoproteins to HDL, with back-transfer of cholesteryl ester from HDL to triglyceride-rich lipoproteins. 12 In accordance with our study, triglycerides increased and HDL cholesterol decreased among 115 subjects 3 to 5 hours after a normal breakfast compared with fasting levels. 11 The National Cholesterol Education Program 2 advises that HDL cholesterol be used in the nonfasting state. The only modest increase in triglyceride levels during normal food intake, together with the recent demonstration of high predictive ability of nonfasting triglycerides for risk of cardiovascular events 6 and risk of myocardial infarction, ischemic heart disease, and death, 7 suggests the possibility that nonfasting rather than fasting triglyceride levels could be used for cardiovascular risk prediction. Because we show here that other lipids, lipoproteins, and apolipoproteins, despite being measured in the nonfasting state, all predicted increased risk of cardiovascular events, perhaps nonfasting levels of all lipids, lipoproteins, and apolipoprotein could be used for cardiovascular risk prediction. If implemented, this would simplify blood sampling for lipid profile measurements. It should be considered whether maximum increases in triglycerides of.3 mmol/l, maximum decreases in total and LDL cholesterol of.2 mmol/l, and maximum decreases in HDL cholesterol of.1 mmol/l in response to normal food and fluid intake are of clinical importance. First, analytical and other physiological variation also may influence levels of lipids, lipoproteins, and apolipoproteins, 1 and this variation could be as large as or even larger than that attributed to normal food intake in the present study. Second, cardiovascular risk assessment is not based only on levels of lipids and lipoproteins, but these values are used with several other risk factors to estimate absolute 1-year risk of ischemic heart disease or cardiovascular death. 2,3 Therefore, these minor changes in lipid and lipoprotein levels after normal food intake will have only minimal influence on the estimated 1-year risk and thus on whether patients should be offered lipid-lowering therapy. Third, neither American nor European guidelines on cardiovascular disease prevention use triglycerides for calculating 1-year risk, 2,3 the lipid value mostly affected by normal food intake; American guidelines suggest evaluating non-hdl cholesterol rather than triglycerides, 2 and non-hdl cholesterol was unaffected by normal food intake in the present study. Fourth, because European guidelines suggest that cardiovascular risk prediction is just as good regardless of whether HDL cholesterol is included, a minimal change in HDL cholesterol of.1 mmol/l resulting from normal food intake certainly would not have a major impact on cardiovascular risk prediction. Finally, statin trials have documented that clinically important reductions in total and LDL cholesterol should be 1 mmol/l, 2,3 also questioning whether a change in the detected levels of total and LDL cholesterol of.2 mmol/l resulting from normal food intake is clinically important. Most previous studies have focused on the change in levels of lipids, lipoproteins, and apolipoproteins after a fat toler-

7 Langsted et al Normal Food Intake, Lipid Profiles, and CVD 253 Table 2. Continued Time Since Last Meal, h Fasting (.1.). (.1.1).1 (..2). (.1.2)..1 (.2.). (.1.1).1 (..2).1 (..3)..1(.1.)*.1 (.1.). (.1.).1 (.1.).. (.1.1). (.1.1).1 (..3).1 (.1.2)..2 (.2.3).1 (.1.2).1 (..2). (.1.1)..9 ( ).8 ( 3.1 ).7 ( 3.8 ) 3.4 ( 7..2). 1.1 ( ) 1.8 (.8 4.3) 2.9 (.6 6.4) ( )..1 (..2).1 (..2).1 (..3).1 (..3).. (.1.1). (.1.1). (.1.2). (.2.2). 2( 6 3) 4 ( 1 8) 4 ( 2 1) 2( 1 6). ance test rather than after normal food intake. These studies usually have the participants consume a meal containing a so-called oral fat load of 1 g of fat per 1 kg body weight 5,7,13,14 and detect increases in triglycerides of 1 to 2 mmol/l. However, most studies find that 3 g fat in a meal has no or very little effect on postprandial lipidemia, which is in accordance with the present demonstration of at most minimal changes in levels of lipids, lipoproteins, and apolipoproteins in response to normal food intake in individuals in the general population. In support of our findings that nonfasting lipids, lipoproteins, and apolipoproteins predict cardiovascular events, previous studies including 7735 men and 258 men found that upper versus lower quartiles or quintiles of nonfasting levels of total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B predicted a 2- to 3-fold increased risk of ischemic heart disease. 18,19 This is similar to the corresponding risk estimates found for upper versus lower tertiles or quintiles of mainly fasting levels of LDL cholesterol, triglycerides, and apolipoprotein B of 2- to 3-fold Similarly, lower versus upper quartiles or quintiles of nonfasting HDL cholesterol and apolipoprotein A1 predicted a 2- to -fold risk of ischemic heart disease in men, 18,19 whereas corresponding values for mainly fasting levels were 2- to 3-fold. 2,22 Importantly, nonfasting triglycerides may be as good as or even better than fasting triglycerides at predicting risk of cardiovascular events. 6,7,23 In addition, apolipoproteins can be used as predictors measured in the nonfasting state, 24 as confirmed in the present study. One limitation of the present study is that we did not draw blood from the same individuals in the fasting state and at fixed intervals after the last meal. However, even after adjustment for all covariates shown in Table II of the online-only Data Supplement, the results were similar to those present in our study. Nevertheless, significant differences can be seen in clinical and demographic characteristics in fasting versus nonfasting participants, as illustrated in Table II of the online-only Data Supplement, and although multivariable adjustment was applied in an attempt to address these differences, the concern about residual confounding in a nonrandomized observational study cannot be totally excluded. The relatively small number of participants with fasting status as the comparison group is another limitation because it might decrease power to detect statistically significant differences between fasting and nonfasting values. A third limitation is that we had no record of exactly what each participant had eaten before blood sampling. On the other hand, our study represents the real world where usually no such information is available before blood sampling. Fourth, it could be argued that the time since the last meal was self-reported and subject to error; however, the time since the last meal was not part of the questionnaire but was asked directly by the examiner at the exact time of blood sampling. Fifth, one could argue that fasting before lipid profile measurement is done to improve the accuracy of LDL cholesterol measurements calculated partly from triglycerides and that we demonstrated an increase in triglycerides in response to normal food intake. However, despite the increase in triglycerides, the calculated LDL cholesterol levels did not change after normal food intake after adjustment for hemodilution resulting from fluid intake. Sixth, the participants in the cross-sectional study were recruited in 21 to 26, and the participants in the prospective study were recruited in 1991 to 1994 and then followed up for 14 years, which imply some differences in levels of cardiovascular risk factors in the 2 studies. Such differences could affect the results; however, in the prospective study, we adjusted hazard ratios for conventional cardiovascular risk factors. Finally, in the present study, we include mainly whites of Danish descent ( 99%); therefore, our results may not necessarily apply to other ethnic groups. Future research could include studies on the predictive value of levels of lipids, lipoproteins, and apolipoproteins for cardiovascular disease risk according to the time since the last meal before blood sampling. Interestingly, a recent metaanalysis found that fasting and nonfasting triglyceride levels were equally good at predicting increased risk of coronary heart disease, 21 whereas another recent study showed that

8 254 Circulation November 11, 28 Table 3. Risk of Cardiovascular Events as a Function of Nonfasting Lipids, Lipoproteins, and Apolipoproteins in the General Population (Copenhagen City Heart Study) Women Approximate Tertiles Incidence/1 person-y Hazard Ratio (95% CI) n Model 1 Model 2 P for Trend Total cholesterol, mmol/l Lower tertile Middle tertile (.8 1.8) 1.4 (.9 2.3) Higher tertile ( ) 1.9 ( ) Non-HDL cholesterol, mmol/l Lower tertile Middle tertile (1.-2.4) (1. 2.4) Higher tertile ( 3.4) 2.1 ( ) LDL cholesterol, mmol/l Lower tertile Middle tertile (.9 2.1) 1.6 (1. 2.4) Higher tertile ( ) 2.2 ( ) HDL cholesterol, mmol/l Higher tertile Middle tertile (1. 1.8) 1.2 (.9 1.7) Lower tertile ( ) 1.7 ( ) Apolipoprotein A1, mg/dl Higher tertile Middle tertile (.9 1.8) 1.2 (.8 1.7) Lower tertile ( ) 1.6 ( ) Apolipoprotein B, mg/dl Lower tertile Middle tertile (1. 1.8) 1.4 (1. 1.9) Higher tertile ( ) 1.8 ( ) Triglycerides, mmol/l Lower tertile Middle tertile (.7 1.6).9 (.6 1.4) Higher tertile ( ) 1.4 (.9 2.2) Total cholesterol/hdl cholesterol Lower tertile Middle tertile (1.3 ) 1.8 ( ) Higher tertile ( ) 2.4 ( ) Apolipoprotein B/apolipoprotein A1 Lower tertile Middle tertile ( ) 1.3 (1. 1.8) Higher tertile ( ) 2.1 ( 2.8) (Continued) CI indicates confidence interval. Model 1 was adjusted for age, blood pressure, smoking, use of lipid-lowering drugs, and use of hormone replacement therapy. Model 2 was adjusted for the covariates in model 1 plus diabetes mellitus, body mass index, and high-sensitivity C-reactive protein. Model 2 has slightly fewer participants than model 1 because of the reduced availability of covariates. All hazard ratios were adjusted for regression dilution bias. nonfasting triglycerides were better than fasting triglycerides at predicting cardiovascular events. 6 Furthermore, we recently documented that a nonfasting triglyceride level of 5 versus 1 mmol/l predicts an age-adjusted 5- and 17-fold increased risk of myocardial infarction in men and women. 7 Therefore, and because atherogenesis may be a postprandial phenomenon, 15,25,26 future research should focus on studies reducing the levels of nonfasting triglycerides and thus remnant lipoprotein cholesterol in an attempt to reduce the risk of cardiovascular disease and death further than that currently obtained by reducing mainly LDL cholesterol levels.

9 Langsted et al Normal Food Intake, Lipid Profiles, and CVD 255 Table 3. Continued Men Approximate Tertiles n Incidence/1 person-y Hazard Ratio (95% CI) Model 1 Model 2 P for Trend (.6 1.4) 1.1 (.7 1.6) ( ) 1.7 (1.1 ) (.6 1.4) 1.1 (.7 1.8) ( ) 2.2 ( ) (.8 1.7) 1.3 (.8 2.) ( ) 1.8 ( ) (1.1 2.) 1.6 ( ) (1.4 ) 2. ( ) (1. 1.9) 1.2 (.9 1.6) (1.3 ) 1.7 ( ) (.8 1.4) 1.1 (.8 1.6) ( ) 1.8 ( ) (.9 2.1) 1.3 (.8 2.1) ( ) 1.8 ( ) (.8 ) 1.1 (.8 1.6) ( 2.8) 2.2 ( ) (.8 1.4) 1.1 (.8 ) ( ) 2.1 ( 2.8) If nonfasting rather than fasting lipid profiles for cardiovascular risk prediction were used, it would simplify clinical care for patients worldwide. Because we detected only minimal changes in levels of lipids, lipoproteins, and apolipoproteins in response to normal food intake in the general population, changes that are clinically unimportant, and because nonfasting levels predict cardiovascular events, our data challenge the necessity for asking patients to fast before measurement of lipid profiles for cardiovascular risk prediction. Sources of Funding This work was funded by the Danish Medical Research Council and the Copenhagen County Foundation. These are public research funds with no right to approve or disapprove the submitted manuscript. Disclosures Dr Nordestgaard is a consultant for Abbott, BG Medicine, and AstraZeneca and has received lecture honoraria from AstraZeneca, Merck, Pfizer, Sanofi-Aventis, and Boehringer Ingelheim. The other authors report no conflicts.

10 256 Circulation November 11, 28 References 1. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Philadelphia, Pa: Elsevier Saunders; 26: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 21;285: De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger C, V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 23;24: Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res. 1988;29: Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, Augustin JL, Seman LJ, Rubenstein JJ. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol. 21;88: Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 27;298: Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 27;298: Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, Gronholdt ML, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med. 1997;127: Altman DG. Practical Statistics for Medical Research. 1st ed. London, UK: Chapman & Hall; 1991: Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;15: Wilder LB, Bachorik PS, Finney CA, Moy TF, Becker DM. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med. 1995;99: Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995; 41: Cohen JC, Noakes TD, Benade AJ. Serum triglyceride responses to fatty meals: effects of meal fat content. Am J Clin Nutr. 1988;47: Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, Pauli AM, Borel P, Latge C, Lairon D. Effects of graded amounts ( 5 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr. 1998;67: Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12: Murphy MC, Isherwood SG, Sethi S, Gould BJ, Wright JW, Knapper JA, Williams CM. Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase? Eur J Clin Nutr. 1995;49: Jeppesen J, Chen YD, Zhou MY, Wang T, Reaven GM. Effect of variations in oral fat and carbohydrate load on postprandial lipemia. Am J Clin Nutr. 1995;62: Pocock S, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides and total cholesterol in ischaemic heart disease. BMJ. 1989;298: Talmud P, Hawe E, Miller G, Humphries S. Non-fasting apolipoprotein B and triglyceride levels as useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 22;22: Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 26; 259: Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 1,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 27;115: Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, for the Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 21;14: Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 23;163: Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 24;155: Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;6: Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem. 25;12: CLINICAL PERSPECTIVE Lipid profiles are usually measured after fasting; however, it would be much simpler for patients if a random nonfasting sample could be used. We tested the hypotheses that lipid profiles change only minimally in response to normal food intake and that random nonfasting levels predict cardiovascular events. We cross-sectionally studied adults from the Copenhagen General Population Study and 9319 adults from the Copenhagen City Heart Study, of whom 1166 developed cardiovascular events during 14 years of follow-up. After normal food intake, individuals in the general population had a maximum mean change from fasting levels of.2 mmol/l ( 8 mg/dl) for total cholesterol at to 2 hours after the last meal,.2 mmol/l ( 8 mg/dl) for low-density lipoprotein cholesterol at to 2 hours,.1 mmol/l ( 4 mg/dl) for high-density lipoprotein cholesterol at to 5 hours, and.3 mmol/l (26 mg/dl) for triglycerides at 1 to 4 hours after the last meal. Highest versus lowest tertile of nonfasting total cholesterol, non high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, ratio of total to high-density lipoprotein cholesterol, and ratio of apolipoprotein B to apolipoprotein A1 and lowest versus highest tertile of nonfasting high-density lipoprotein cholesterol and apolipoprotein A1 predicted 1.7- to 2.4-fold increased risk of cardiovascular events. Because we detected only minimal changes in levels of lipids, lipoproteins, and apolipoproteins in response to normal food intake in the general population, changes that are clinically unimportant, and because nonfasting levels predict cardiovascular events, our data challenge the necessity for asking patients to fast before measurement of lipid profiles for cardiovascular risk prediction.

Epidemiology. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events

Epidemiology. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Epidemiology Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Samia Mora, MD, MHS; Nader Rifai, PhD; Julie E. Buring, ScD; Paul M Ridker, MD, MPH

More information

HYPERTRIGLYCERIDEMIA IS A

HYPERTRIGLYCERIDEMIA IS A ORIGINAL CONTRIBUTION Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women Børge G. Nordestgaard, MD, DMSc Marianne Benn, MD, PhD Peter Schnohr,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.

More information

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.

More information

The Second Report of the Expert Panel on Detection,

The Second Report of the Expert Panel on Detection, Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare

More information

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required

More information

THE ROLE OF TRIGLYCERIDES IN

THE ROLE OF TRIGLYCERIDES IN ORIGINAL CONTRIBUTION Nonfasting Triglycerides and Risk of Ischemic in the General Population Jacob J. Freiberg, MD Anne Tybjærg-Hansen, MD, DMSc Jan Skov Jensen, MD, DMSc Børge G. Nordestgaard, MD, DMSc

More information

Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk

Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-13-2016 Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Richard

More information

Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study

Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study Marianne Benn, Børge G. Nordestgaard, Gorm Boje Jensen, Anne Tybjærg-Hansen

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple

More information

ANUMBER OF EPIDEMIOLOGIcal

ANUMBER OF EPIDEMIOLOGIcal ORIGINAL INVESTIGATION The Independent Effect of Type Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death A Population-Based Study of Men and Women With Years of Follow-up Thomas Almdal, DMSc;

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease The new england journal of medicine original article Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease Jeppe Zacho, M.D., Anne Tybjærg-Hansen, M.D., D.M.Sc., Jan Skov Jensen, M.D.,

More information

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

Recently reported clinical trials have provided strong

Recently reported clinical trials have provided strong Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions The Atherosclerosis Risk in Communities (ARIC)

More information

Threshold Level or Not for Low-Density Lipoprotein Cholesterol

Threshold Level or Not for Low-Density Lipoprotein Cholesterol ... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

POSTPRANDIAL HYPERTRIGLYCERIDAEMIA AND VASCULAR RISK. Dept. of Clinical Biochemistry Royal Free campus University College London (UCL)

POSTPRANDIAL HYPERTRIGLYCERIDAEMIA AND VASCULAR RISK. Dept. of Clinical Biochemistry Royal Free campus University College London (UCL) POSTPRANDIAL HYPERTRIGLYCERIDAEMIA AND VASCULAR RISK D P Mikhailidis BSc MSc MD FCPP FCP FRSPH FFPM FRCP FRCPath Dept. of Clinical Biochemistry Royal Free campus University College London (UCL) DECLARATION

More information

Assessment of clinical profile of coronary artery disease in Indian Population

Assessment of clinical profile of coronary artery disease in Indian Population Original article: Assessment of clinical profile of coronary artery disease in Indian Population 1Dr J S Dhadwad, 2 Dr N G Karandikar 1 Assistant Professor, Department of Medicine, P. Dr. D Y Patil Medical

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Journal of the American College of Cardiology Vol. 59, No. 17, by the American College of Cardiology Foundation ISSN /$36.

Journal of the American College of Cardiology Vol. 59, No. 17, by the American College of Cardiology Foundation ISSN /$36. Journal of the American College of Cardiology Vol. 59, No. 17, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.035

More information

The apolipoprotein story

The apolipoprotein story Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

SUMMARY. Introduction. Study design. Summary

SUMMARY. Introduction. Study design. Summary SUMMARY Introduction The global prevalence of type 2 diabetes is increasing rapidly and nowadays affects almost 250 million people. Cardiovascular disease is the most prevalent complication of type 2 diabetes,

More information

Zuhier Awan, MD, PhD, FRCPC

Zuhier Awan, MD, PhD, FRCPC Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

More information

The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)

The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Recruitment The majority of participants in the GOLDN Study were re-recruited from threegenerational pedigrees from two National Heart, Lung

More information

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,

More information

Diabetes, Diet and SMI: How can we make a difference?

Diabetes, Diet and SMI: How can we make a difference? Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative

More information

Ischemic heart disease (IHD) is the most common cause of

Ischemic heart disease (IHD) is the most common cause of Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease The Copenhagen City Heart Study Birgit Agerholm-Larsen, MSc, PhD; Anne

More information

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused

More information

MYOCARDIAL INFARCTION

MYOCARDIAL INFARCTION ORIGINAL CONTRIBUTION Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction Pia R. Kamstrup, MD, PhD Anne Tybjærg-Hansen, MD, DMSc Rolf Steffensen, MD Børge G. Nordestgaard, MD,

More information

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown

More information

The Framingham Risk Score (FRS) is widely recommended

The Framingham Risk Score (FRS) is widely recommended C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore

More information

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND

More information

EPIDEMIOLOGICAL STUDIES CONSIStently

EPIDEMIOLOGICAL STUDIES CONSIStently ORIGINAL CONTRIBUTION Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease Ruth Frikke-Schmidt, MD, PhD Børge

More information

Re-assessing the role of non-fasting lipids; a change in perspective

Re-assessing the role of non-fasting lipids; a change in perspective Editorial Page 1 of 5 Re-assessing the role of non-fasting lipids; a change in perspective Zareen Farukhi 1,2, Samia Mora 1,2 1 Center for Lipid Metabolomics, Division of Preventive Medicine, 2 Department

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

A lthough the hazards of smoking are well described,

A lthough the hazards of smoking are well described, 702 RESEARCH REPORT Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Raising high-density lipoprotein cholesterol: where are we now?

Raising high-density lipoprotein cholesterol: where are we now? European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;

More information

8/10/2012. Education level and diabetes risk: The EPIC-InterAct study AIM. Background. Case-cohort design. Int J Epidemiol 2012 (in press)

8/10/2012. Education level and diabetes risk: The EPIC-InterAct study AIM. Background. Case-cohort design. Int J Epidemiol 2012 (in press) Education level and diabetes risk: The EPIC-InterAct study 50 authors from European countries Int J Epidemiol 2012 (in press) Background Type 2 diabetes mellitus (T2DM) is one of the most common chronic

More information

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,

More information

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

sad EFFECTIVE DATE: POLICY LAST UPDATED:

sad EFFECTIVE DATE: POLICY LAST UPDATED: Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),

More information

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments

More information

REVIEW ARTICLE REVIEW ARTICLE. Fasting versus non-fasting Lipid profile in the clinical practice

REVIEW ARTICLE REVIEW ARTICLE. Fasting versus non-fasting Lipid profile in the clinical practice REVIEW ARTICLE REVIEW ARTICLE DOI: http://doi.org/10.4038/sjdem.v8i2.7355 Fasting versus non-fasting Lipid profile in the clinical practice Umakanth M Faculty of Health care sciences, Eastern university-sri

More information

CLINICAL RESEARCH STUDY

CLINICAL RESEARCH STUDY CLINICAL RESEARCH STUDY Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, a Bhakti Arondekar, BPharm, MBA, PhD, b Erin

More information

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study Jaakko Mursu, Jyrki K. Virtanen, Tiina H. Rissanen,

More information

thematic review series

thematic review series thematic review series Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology Børge G. Nordestgaard

More information

The importance of both low-density lipoprotein

The importance of both low-density lipoprotein Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol Steven A. Grover, 1,2,3,4 Marc Dorais, 1,3 and Louis Coupal 1,3 Background. The ratio of total cholesterol to

More information

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International

More information

Regence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment

Regence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Regence Medical Policy Manual Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Date of Origin: May 2013 Section: Genetic Testing Last Reviewed Date: June 2013

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

Saturated fat- how long can you go/how low should you go?

Saturated fat- how long can you go/how low should you go? Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease Journal of the American College of Cardiology Vol. 55, No. 25, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.02.044

More information

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36. Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Coronary heart disease (CHD) is the leading cause of

Coronary heart disease (CHD) is the leading cause of Serum Albumin and Risk of Myocardial Infarction and All-Cause Mortality in the Framingham Offspring Study Luc Djoussé, MD, DSc; Kenneth J. Rothman, DrPH; L. Adrienne Cupples, PhD; Daniel Levy, MD; R. Curtis

More information

Patients with type 2 diabetes are at

Patients with type 2 diabetes are at Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease

Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease Lipids and cardiovascular disease Triglycerides and cardiovascular disease Børge G Nordestgaard, Anette Varbo Lancet ; 8: 66 6 This is the third in a Series of three papers about lipids and cardiovascular

More information

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,

More information

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk cobas modular platform Flexible configurations for tailormade solutions With the cobas modular platform (cobas

More information

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community International Journal of Scientific and Research Publications, Volume 4, Issue 4, April 214 1 The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community Mulugeta

More information

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION 1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

The ACCELERATE Trial

The ACCELERATE Trial The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,

More information

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal

More information

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease The new england journal of medicine original article Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease Anders Berg Jørgensen, M.D., Ph.D., Ruth Frikke-Schmidt, M.D., D.M.Sc., Børge

More information